Early efficacy observed with trastuzumab deruxtecan ± pertuzumab for HER2+ metastatic breast cancer

Data from the phase 1b/2 DESTINY-Breast07 trial—presented during the 2022 San Antonio Breast Cancer Symposium—suggest that the use of trastuzumab deruxtecan with or without pertuzumab may provide benefit for patients with HER2-positive metastatic breast cancer.